Jacobs Levy Equity Management’s LENZ Therapeutics LENZ Stock Holding History

Jacobs Levy Equity Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$91.2K	Sell	16,061 -100,950	-86%	-$814K	﹤0.01%	925
2026 Q1	$1.07M	Sell	117,011 -153,908	-57%	-$2.16M	﹤0.01%	693
2025 Q4	$4.33M	Buy	+270,919	New	+$7.9M	0.02%	437
2024 Q2	–	Sell	-37,176	Closed	-$830K	–	1060
2024 Q1	$830K	Buy	37,176 +10,598	+40%	+$220K	﹤0.01%	748
2023 Q4	$487K	Hold	26,578	–	–	﹤0.01%	833
2023 Q3	$461K	Hold	26,578	–	–	﹤0.01%	817
2023 Q2	$484K	Buy	+26,578	New	+$531K	﹤0.01%	828

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Jacobs Levy Equity Management's LENZ Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its LENZ Therapeutics (LENZ) stake by 86% in Q2 2026, selling an estimated $814K and leaving 16,061 shares worth $91.2K. The position accounts for ﹤0.01% of the portfolio, ranked #925.

Jacobs Levy Equity Management first reported a position in LENZ in Q2 2023 and has held it in 7 quarters since. The position peaked at $4.33M in Q4 2025. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

Jacobs Levy Equity Management held 16,061 shares of LENZ Therapeutics worth $91.2K as of Q2 2026.
Jacobs Levy Equity Management sold 100,950 LENZ Therapeutics shares in Q2 2026, an estimated $814K.
LENZ Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #925 holding.
Jacobs Levy Equity Management first reported a position in LENZ Therapeutics in Q2 2023 and has held it in 7 quarters since.
Jacobs Levy Equity Management's LENZ Therapeutics position peaked at $4.33M in Q4 2025.
144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.